The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The impact of acalabrutinib treatment by line of therapy in patients with CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses a study investigating the impact of acalabrutinib treatment by line of therapy in patients with chronic lymphocytic leukemia (CLL). The results indicate that patients have better outcomes when acalabrutinib is administered as a frontline or second-line treatment compared to later lines of therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Consultancy: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Honoraria: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche.
